This review explores the mechanisms of ER stress across all forms of diabetes, discusses both pharmacological and non-pharmacological approaches to modulating ER stress—with particular attention to medications that are already approved for use in children, such as metformin —and examines the potential of combining ER stress modulation with insulin therapy in order to optimize the metabolic homeostasis for the β-cell function and survival. This evidence concerns the gene INS and diabetes mellitus.